328(top 1%)
PR articles
34.1K(top 0.1%)
PR citations
89(top 0.1%)
PR h-index
96(top 0.1%)
h-index
348
documents
40.8K
doc citations
4.1K
citing journals
100
times ranked

Publications

330 PR articles • 35,212 PR citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study
Lancet Microbe, The, 2025, 6, 100922
12.320Citations (PDF)
2R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18–45 years: an open-label, partially blinded, phase 1–2a controlled human malaria infection study
Lancet Microbe, The, 2025, 6, 100867
12.37Citations (PDF)
3A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Science Translational Medicine, 2025, 17,
12.52Citations (PDF)
4Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot
Science Translational Medicine, 2025, 17,
12.50Citations (PDF)
5Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine
Journal of Experimental Medicine, 2025, 222,
9.24Citations (PDF)
6A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy
American Journal of Human Genetics, 2024, 111, 295-308
6.52Citations (PDF)
7High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response
Nature Medicine, 2024, 30, 1384-1394
33.011Citations (PDF)
8A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults
Npj Vaccines, 2024, 9,
5.36Citations (PDF)
9A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates
Science Translational Medicine, 2024, 16,
12.57Citations (PDF)
10An adenoviral-vectored vaccine confers seroprotection against capsular group B meningococcal disease
Science Translational Medicine, 2023, 15,
12.55Citations (PDF)
11Mexican Biobank advances population and medical genomics of diverse ancestries
Nature, 2023, 622, 775-783
37.9109Citations (PDF)
12A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice
Molecular Therapy, 2022, 30, 2024-2047
10.234Citations (PDF)
13Imputation Performance in Latin American Populations: Improving Rare Variants Representation With the Inclusion of Native American Genomes
Frontiers in Genetics, 2022, 12,
2.313Citations (PDF)
14Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria
Frontiers in Immunology, 2022, 13,
4.916Citations (PDF)
15CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination
JCI Insight, 2022, 7,
5.411Citations (PDF)
16Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
JCI Insight, 2022, 7,
5.437Citations (PDF)
17Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank
Nature Communications, 2022, 13,
13.767Citations (PDF)
18A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes
Journal of Experimental Medicine, 2022, 219,
9.259Citations (PDF)
19Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
Biotechnology and Bioengineering, 2022, 119, 2784-2793
3.96Citations (PDF)
20Ancient DNA reveals five streams of migration into Micronesia and matrilocality in early Pacific seafarers
Science, 2022, 377, 72-79
36.230Citations (PDF)
21Genome-wide association study of leprosy in Malawi and Mali
PLoS Pathogens, 2022, 18, e1010312
4.44Citations (PDF)
22Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Lancet, The, 2021, 397, 99-111
62.34,401Citations (PDF)
23Malaria is a cause of iron deficiency in African children
Nature Medicine, 2021, 27, 653-658
33.054Citations (PDF)
24Low immunogenicity of malaria pre‐erythrocytic stages can be overcome by vaccination
EMBO Molecular Medicine, 2021, 13,
7.112Citations (PDF)
25Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Lancet, The, 2021, 397, 881-891
62.31,097Citations (PDF)
26Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Lancet, The, 2021, 397, 1351-1362
62.3592Citations (PDF)
27Ultra-low dose immunization and multi-component vaccination strategies enhance protection against malaria in mice
Scientific Reports, 2021, 11,
3.419Citations (PDF)
28Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
Lancet, The, 2021, 397, 1809-1818
62.3399Citations (PDF)
29Dissection-independent production ofPlasmodiumsporozoites from whole mosquitoes
Life Science Alliance, 2021, 4, e202101094
2.67Citations (PDF)
30A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
Nature Communications, 2021, 12,
13.756Citations (PDF)
31Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites
PLoS ONE, 2021, 16, e0254498
2.32Citations (PDF)
32Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Lancet HIV,the, 2021, 8, e474-e485
7.9230Citations (PDF)
33A three-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults
PLoS ONE, 2021, 16, e0256980
2.317Citations (PDF)
34Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans
Frontiers in Immunology, 2021, 12,
4.99Citations (PDF)
35Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Nature Medicine, 2021, 27, 2032-2040
33.01,113Citations (PDF)
36Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
2021, 9, e003218
23Citations (PDF)
37Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Lancet, The, 2021, 398, 981-990
62.3247Citations (PDF)
38Paths and timings of the peopling of Polynesia inferred from genomic networks
Nature, 2021, 597, 522-526
37.958Citations (PDF)
39Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation
Scientific Reports, 2021, 11,
3.44Citations (PDF)
40Identification of antigens presented by MHC for vaccines against tuberculosis
Npj Vaccines, 2020, 5,
5.3101Citations (PDF)
41Targeting Antigen to the Surface of EVs Improves the In Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice
Molecular Therapy - Methods and Clinical Development, 2020, 16, 108-125
4.148Citations (PDF)
42Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Lancet, The, 2020, 396, 467-478
62.32,309Citations (PDF)
43Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Lancet, The, 2020, 396, 1979-1993
62.31,338Citations (PDF)
44The Human Leukocyte Antigen Locus and Rheumatic Heart Disease Susceptibility in South Asians and Europeans
Scientific Reports, 2020, 10,
3.414Citations (PDF)
45Risk of pneumococcal bacteremia in Kenyan children with glucose-6-phosphate dehydrogenase deficiency
BMC Medicine, 2020, 18,
7.17Citations (PDF)
46Generation of Novel Plasmodium falciparum NF135 and NF54 Lines Expressing Fluorescent Reporter Proteins Under the Control of Strong and Constitutive Promoters
Frontiers in Cellular and Infection Microbiology, 2020, 10,
4.118Citations (PDF)
47Estimating the burden of iron deficiency among African children
BMC Medicine, 2020, 18,
7.164Citations (PDF)
48Native American gene flow into Polynesia predating Easter Island settlement
Nature, 2020, 583, 572-577
37.998Citations (PDF)
49Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
2020, 8, e000928
35Citations (PDF)
50Preclinical Development and Assessment of Viral Vectors Expressing a Fusion Antigen of Plasmodium falciparum LSA1 and LSAP2 for Efficacy against Liver-Stage Malaria
Infection and Immunity, 2020, 88,
2.79Citations (PDF)
51Modification of Adenovirus vaccine vector-induced immune responses by expression of a signalling molecule
Scientific Reports, 2020, 10,
3.412Citations (PDF)
52Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
Lancet Infectious Diseases, The, 2020, 20, 816-826
16.5218Citations (PDF)
53Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Nature Medicine, 2020, 27, 279-288
33.0306Citations (PDF)
54T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Nature Medicine, 2020, 27, 270-278
33.0548Citations (PDF)
55TMEM203 is a binding partner and regulator of STING-mediated inflammatory signaling in macrophages
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16479-16488
7.554Citations (PDF)
56Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
Npj Vaccines, 2019, 4,
5.337Citations (PDF)
57The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia
Science Advances, 2019, 5,
10.926Citations (PDF)
58Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal
Journal of Infectious Diseases, 2019, 219, 1187-1197
3.878Citations (PDF)
59Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization
Cell Reports, 2019, 27, 3241-3253.e4
6.329Citations (PDF)
60A P. falciparum NF54 Reporter Line Expressing mCherry-Luciferase in Gametocytes, Sporozoites, and Liver-Stages
Frontiers in Cellular and Infection Microbiology, 2019, 9,
4.133Citations (PDF)
61Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Vaccines, 2019, 7, 40
2.924Citations (PDF)
62Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Vaccines, 2019, 7, 33
2.925Citations (PDF)
63Use of gene expression studies to investigate the human immunological response to malaria infection
Malaria Journal, 2019, 18,
2.614Citations (PDF)
64Iron Status and Associated Malaria Risk Among African Children
Clinical Infectious Diseases, 2019, 68, 1807-1814
5.246Citations (PDF)
65Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii
PLoS ONE, 2019, 14, e0210407
2.322Citations (PDF)
66Elevated risk of invasive group A streptococcal disease and host genetic variation in the human leucocyte antigen locus
Genes and Immunity, 2019, 21, 63-70
3.87Citations (PDF)
67Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP
Scientific Reports, 2018, 8,
3.441Citations (PDF)
68Language continuity despite population replacement in Remote Oceania
Nature Ecology and Evolution, 2018, 2, 731-740
9.6116Citations (PDF)
69Genetic variation in VAC14 is associated with bacteremia secondary to diverse pathogens in African children
Proceedings of the National Academy of Sciences of the United States of America, 2018, 115,
7.513Citations (PDF)
70Risk of nontyphoidal Salmonella bacteraemia in African children is modified by STAT4
Nature Communications, 2018, 9,
13.731Citations (PDF)
71DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines
Diseases (Basel, Switzerland), 2018, 6, 107
2.79Citations (PDF)
72First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children
PLoS ONE, 2018, 13, e0208328
2.363Citations (PDF)
73CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria
Frontiers in Immunology, 2018, 9,
4.943Citations (PDF)
74Prime and target immunization protects against liver-stage malaria in mice
Science Translational Medicine, 2018, 10,
12.579Citations (PDF)
75Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses
Scientific Reports, 2018, 8,
3.422Citations (PDF)
76A simian-adenovirus-vectored rabies vaccine suitable for thermostabilisation and clinical development for low-cost single-dose pre-exposure prophylaxis
PLoS Neglected Tropical Diseases, 2018, 12, e0006870
3.048Citations (PDF)
77Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP
Npj Vaccines, 2018, 3,
5.356Citations (PDF)
78Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors
Nature Communications, 2018, 9,
13.783Citations (PDF)
79Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials
Vaccines, 2018, 6, 50
2.979Citations (PDF)
80Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens
Journal of Immunology, 2018, 201, 1315-1326
0.640Citations (PDF)
81Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors
Infection and Immunity, 2018, 86,
2.741Citations (PDF)
82Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model
Scientific Reports, 2018, 8,
3.419Citations (PDF)
83Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
Vaccine Journal, 2017, 24,
3.123Citations (PDF)
84Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis
Science Advances, 2017, 3,
10.952Citations (PDF)
85Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants
Molecular Therapy, 2017, 25, 547-559
10.243Citations (PDF)
86Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models
Scientific Reports, 2017, 7,
3.451Citations (PDF)
87Association between a common immunoglobulin heavy chain allele and rheumatic heart disease risk in Oceania
Nature Communications, 2017, 8,
13.7137Citations (PDF)
88Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine
Scientific Reports, 2017, 7,
3.4235Citations (PDF)
89ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Vaccine, 2017, 35, 3780-3788
3.1152Citations (PDF)
90Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy
Vaccine, 2017, 35, 1898-1906
3.146Citations (PDF)
91Shared and Distinct Aspects of the Sepsis Transcriptomic Response to Fecal Peritonitis and Pneumonia
American Journal of Respiratory and Critical Care Medicine, 2017, 196, 328-339
8.9234Citations (PDF)
92Chimpanzee adenoviral vectors as vaccines for outbreak pathogens
Human Vaccines and Immunotherapeutics, 2017, 13, 3020-3032
3.180Citations (PDF)
93Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™
Vaccine, 2017, 35, 6208-6217
3.134Citations (PDF)
94Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
Scientific Reports, 2017, 7,
3.416Citations (PDF)
95An in vitro assay to measure antibody-mediated inhibition of P. berghei sporozoite invasion against P. falciparum antigens
Scientific Reports, 2017, 7,
3.421Citations (PDF)
96Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial
Frontiers in Immunology, 2017, 8,
4.926Citations (PDF)
97Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies
JCI Insight, 2017, 2,
5.496Citations (PDF)
98Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions
JCI Insight, 2017, 2,
5.4136Citations (PDF)
99Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection
Vaccines, 2016, 4, 27
2.938Citations (PDF)
100Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal
PLoS ONE, 2016, 11, e0167951
2.350Citations (PDF)
101Potency of a thermostabilised chimpanzee adenovirus Rift Valley Fever vaccine in cattle
Vaccine, 2016, 34, 2296-2298
3.133Citations (PDF)
102Genetic Factors of the Disease Course after Sepsis: A Genome-Wide Study for 28 Day Mortality
EBioMedicine, 2016, 12, 239-246
9.762Citations (PDF)
103Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever
Scientific Reports, 2016, 6,
3.4110Citations (PDF)
104Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
Molecular Therapy, 2016, 24, 1470-1477
10.263Citations (PDF)
105Viral vectors as vaccine platforms: from immunogenicity to impact
Current Opinion in Immunology, 2016, 41, 47-54
5.2168Citations (PDF)
106Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01BWith Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP
Journal of Infectious Diseases, 2016, 214, 772-781
3.8108Citations (PDF)
107Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children
American Journal of Human Genetics, 2016, 98, 1092-1100
6.544Citations (PDF)
108A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA
New England Journal of Medicine, 2016, 374, 1635-1646
34.6322Citations (PDF)
109Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter
Vaccine, 2016, 34, 49-55
3.115Citations (PDF)
110Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
Lancet Infectious Diseases, The, 2016, 16, 31-42
16.5207Citations (PDF)
111Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study
Lancet Respiratory Medicine,the, 2016, 4, 259-271
23.4741Citations (PDF)
112Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
Scientific Reports, 2015, 5,
3.440Citations (PDF)
113Distinct Transcriptional and Anti-Mycobacterial Profiles of Peripheral Blood Monocytes Dependent on the Ratio of Monocytes: Lymphocytes
EBioMedicine, 2015, 2, 1619-1626
9.764Citations (PDF)
114Malaria vaccines: identifying Plasmodium falciparum liver-stage targets
Frontiers in Microbiology, 2015, 6,
3.924Citations (PDF)
115Rare Variants in MYD88, IRAK4 and IKBKG and Susceptibility to Invasive Pneumococcal Disease: A Population-Based Case-Control Study
PLoS ONE, 2015, 10, e0123532
2.38Citations (PDF)
116Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PfLSA1 and PfLSAP2 in Multiple Strains of Mice
PLoS ONE, 2015, 10, e0144515
2.35Citations (PDF)
117Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals
Journal of Infectious Diseases, 2015, 211, 1076-1086
3.8126Citations (PDF)
118Variants in the Mannose-binding Lectin GeneMBL2do not Associate With Sepsis Susceptibility or Survival in a Large European Cohort
Clinical Infectious Diseases, 2015, 61, 695-703
5.225Citations (PDF)
119Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines
American Journal of Tropical Medicine and Hygiene, 2015, 93, 1254-1259
0.06Citations (PDF)
120Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study
Lancet Respiratory Medicine,the, 2015, 3, 53-60
23.4189Citations (PDF)
121The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species
Vaccine, 2015, 33, 1121-1128
3.124Citations (PDF)
122Genomic modulators of gene expression in human neutrophils
Nature Communications, 2015, 6,
13.7135Citations (PDF)
123Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates
Scientific Reports, 2015, 5,
3.452Citations (PDF)
124Genetic susceptibility to invasive Salmonella disease
Nature Reviews Immunology, 2015, 15, 452-463
53.888Citations (PDF)
125Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studies
Malaria Journal, 2015, 14,
2.643Citations (PDF)
126Searching for the human genetic factors standing in the way of universally effective vaccines
Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140341
3.742Citations (PDF)
127Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine
Vaccine, 2015, 33, 3248-3255
3.132Citations (PDF)
128Profiling the host response to malaria vaccination and malaria challenge
Vaccine, 2015, 33, 5316-5320
3.121Citations (PDF)
129Progress with viral vectored malaria vaccines: A multi-stage approach involving “unnatural immunity”
Vaccine, 2015, 33, 7444-7451
3.158Citations (PDF)
130Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8+ T Cells
PLoS ONE, 2015, 10, e0119880
2.318Citations (PDF)
131Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain
PLoS ONE, 2014, 9, e100538
2.335Citations (PDF)
1324-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques
PLoS ONE, 2014, 9, e105520
2.37Citations (PDF)
133A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
Science Translational Medicine, 2014, 6,
12.5325Citations (PDF)
134Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens
Molecular Therapy, 2014, 22, 668-674
10.2186Citations (PDF)
135Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1
Molecular Therapy, 2014, 22, 464-475
10.2198Citations (PDF)
136Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection
Frontiers in Microbiology, 2014, 5,
3.9100Citations (PDF)
137Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
Infection and Immunity, 2014, 82, 1277-1286
2.756Citations (PDF)
138RNA and Imidazoquinolines Are Sensed by Distinct TLR7/8 Ectodomain Sites Resulting in Functionally Disparate Signaling Events
Journal of Immunology, 2014, 192, 5963-5973
0.643Citations (PDF)
139Analysis of human B‐cell responses following ChAd63‐MVA MSP1 and AMA1 immunization and controlled malaria infection
Immunology, 2014, 141, 628-644
4.744Citations (PDF)
140IFITM3 and Susceptibility to Respiratory Viral Infections in the Community
Journal of Infectious Diseases, 2014, 209, 1028-1031
3.874Citations (PDF)
141Ratio of Monocytes to Lymphocytes in Peripheral Blood Identifies Adults at Risk of Incident Tuberculosis Among HIV-Infected Adults Initiating Antiretroviral Therapy
Journal of Infectious Diseases, 2014, 209, 500-509
3.8111Citations (PDF)
142Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine
Vaccine, 2014, 32, 3424-3430
3.14Citations (PDF)
143Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses
Molecular Therapy, 2014, 22, 233-238
10.2104Citations (PDF)
144Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial
Molecular Therapy, 2014, 22, 2142-2154
10.268Citations (PDF)
145Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naive to Malaria-endemic Populations
Molecular Therapy, 2014, 22, 1992-2003
10.254Citations (PDF)
146Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route
Scientific Reports, 2014, 4,
3.452Citations (PDF)
147External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance
PLoS ONE, 2014, 9, e97398
2.330Citations (PDF)
148Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure
PLoS ONE, 2014, 9, e107903
2.368Citations (PDF)
149A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS
PLoS ONE, 2014, 9, e115161
2.350Citations (PDF)
150Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
Nature Communications, 2013, 4,
13.7272Citations (PDF)
151Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
Virology Journal, 2013, 10,
3.655Citations (PDF)
152Identifying Recent Adaptations in Large-Scale Genomic Data
Cell, 2013, 152, 703-713
33.7346Citations (PDF)
153Identification of Targets of CD8+ T Cell Responses to Malaria Liver Stages by Genome-wide Epitope Profiling
PLoS Pathogens, 2013, 9, e1003303
4.477Citations (PDF)
154Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines
Human Vaccines and Immunotherapeutics, 2013, 9, 1741-1751
3.16Citations (PDF)
155Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection
Journal of Infectious Diseases, 2013, 208, 340-345
3.857Citations (PDF)
156Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection
Journal of Immunology, 2013, 190, 1135-1147
0.623Citations (PDF)
157The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment
Scientific Reports, 2013, 3,
3.437Citations (PDF)
158Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe
PLoS ONE, 2013, 8, e65960
2.384Citations (PDF)
159Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice
PLoS ONE, 2013, 8, e67888
2.368Citations (PDF)
160Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults
PLoS ONE, 2013, 8, e57726
2.368Citations (PDF)
161Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
Journal of Infectious Diseases, 2012, 205, 772-781
3.8206Citations (PDF)
162Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine
Vaccine Journal, 2012, 19, 295-303
3.118Citations (PDF)
163Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species
Science Translational Medicine, 2012, 4,
12.5281Citations (PDF)
164Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans
Clinical Infectious Diseases, 2012, 55, 19-25
5.2231Citations (PDF)
165Bayesian refinement of association signals for 14 loci in 3 common diseases
Nature Genetics, 2012, 44, 1294-1301
25.2523Citations (PDF)
166ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans
Molecular Therapy, 2012, 20, 2355-2368
10.2210Citations (PDF)
167Distinguishing malaria and influenza: Early clinical features in controlled human experimental infection studies
Travel Medicine and Infectious Disease, 2012, 10, 192-196
2.511Citations (PDF)
168Common variants at 11p13 are associated with susceptibility to tuberculosis
Nature Genetics, 2012, 44, 257-259
25.2211Citations (PDF)
169Evolution, revolution and heresy in the genetics of infectious disease susceptibility
Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 840-849
3.7122Citations (PDF)
170Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?
Human Vaccines and Immunotherapeutics, 2012, 8, 706-714
3.179Citations (PDF)
171Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
Molecular Therapy, 2012, 20, 1633-1647
10.241Citations (PDF)
172Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates
PLoS ONE, 2012, 7, e33555
2.346Citations (PDF)
173Identification of 34 Novel Proinflammatory Proteins in a Genome-Wide Macrophage Functional Screen
PLoS ONE, 2012, 7, e42388
2.310Citations (PDF)
174T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein
PLoS ONE, 2012, 7, e44943
2.323Citations (PDF)
175A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years
PLoS ONE, 2012, 7, e48322
2.3117Citations (PDF)
176Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
Science Translational Medicine, 2012, 4,
12.5378Citations (PDF)
177Human genetic susceptibility to infectious disease
Nature Reviews Genetics, 2012, 13, 175-188
47.0449Citations (PDF)
178Coated microneedle arrays for transcutaneous delivery of live virus vaccines
Journal of Controlled Release, 2012, 159, 34-42
11.0160Citations (PDF)
179Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors
Biotechnology and Bioengineering, 2012, 109, 719-728
3.950Citations (PDF)
180Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors
PLoS ONE, 2012, 7, e31208
2.3164Citations (PDF)
181Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials
PLoS ONE, 2012, 7, e38434
2.369Citations (PDF)
182A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity
PLoS ONE, 2012, 7, e40385
2.3354Citations (PDF)
183Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
PLoS ONE, 2012, 7, e50447
2.327Citations (PDF)
184The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
Nature Communications, 2011, 2,
13.7264Citations (PDF)
185A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine
Vaccine, 2011, 29, 7514-7522
3.148Citations (PDF)
186Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1
PLoS ONE, 2011, 6, e20977
2.347Citations (PDF)
187Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice
PLoS ONE, 2011, 6, e22442
2.372Citations (PDF)
188Human genetic susceptibility to intracellular pathogens
Immunological Reviews, 2011, 240, 105-116
6.5105Citations (PDF)
189Viral vectors as vaccine platforms: deployment in sight
Current Opinion in Immunology, 2011, 23, 377-382
5.2197Citations (PDF)
190Vaccines and global health
Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2733-2742
3.731Citations (PDF)
191Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors
Molecular Therapy, 2011, 19, 2269-2276
10.2161Citations (PDF)
192Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Clinical Infectious Diseases, 2011, 52, 1-7
5.2434Citations (PDF)
193Vaccines against malaria
Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2806-2814
3.7175Citations (PDF)
194Two Human MYD88 Variants, S34Y and R98C, Interfere with MyD88-IRAK4-Myddosome Assembly
Journal of Biological Chemistry, 2011, 286, 1341-1353
2.272Citations (PDF)
195The Requirement for Potent Adjuvants To Enhance the Immunogenicity and Protective Efficacy of Protein Vaccines Can Be Overcome by Prior Immunization with a Recombinant Adenovirus
Journal of Immunology, 2011, 187, 2602-2616
0.656Citations (PDF)
196Partially Randomized, Non-Blinded Trial of DNA and MVA Therapeutic Vaccines Based on Hepatitis B Virus Surface Protein for Chronic HBV Infection
PLoS ONE, 2011, 6, e14626
2.365Citations (PDF)
197Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909
PLoS ONE, 2011, 6, e22271
2.388Citations (PDF)
198Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass
Science Translational Medicine, 2010, 2,
12.5150Citations (PDF)
199Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2
Nature Genetics, 2010, 42, 739-741
25.2353Citations (PDF)
200Prime-boost vectored malaria vaccines: Progress and prospects
Hum Vaccin, 2010, 6, 78-83
2.8188Citations (PDF)
201A Naturally Occurring Variant in Human TLR9, P99L, Is Associated with Loss of CpG Oligonucleotide Responsiveness
Journal of Biological Chemistry, 2010, 285, 36486-36494
2.228Citations (PDF)
202An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6
Human Molecular Genetics, 2010, 19, 720-730
2.925Citations (PDF)
203Comment on “CRTAM Confers Late-Stage Activation of CD8+ T Cells to Regulate Retention within Lymph Node”
Journal of Immunology, 2010, 184, 4052-4053
0.61Citations (PDF)
204Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8 + T-Cell Responses
Infection and Immunity, 2010, 78, 145-153
2.7185Citations (PDF)
205Leprosy and the Adaptation of Human Toll-Like Receptor 1
PLoS Pathogens, 2010, 6, e1000979
4.4144Citations (PDF)
206Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime–boost immunisation in non-human primates
Vaccine, 2010, 29, 256-265
3.172Citations (PDF)
207Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected Individuals
American Journal of Respiratory and Critical Care Medicine, 2009, 179, 724-733
8.9112Citations (PDF)
208Consanguinity and susceptibility to infectious diseases in humans
Biology Letters, 2009, 5, 574-576
2.564Citations (PDF)
209Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria
Cell Host and Microbe, 2009, 5, 95-105
15.165Citations (PDF)
210Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines
Vaccine, 2009, 27, 5589-5598
3.120Citations (PDF)
211Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
European Journal of Immunology, 2008, 38, 732-741
3.295Citations (PDF)
212Effective induction of high-titer antibodies by viral vector vaccines
Nature Medicine, 2008, 14, 819-821
33.0150Citations (PDF)
213PTPRC (CD45) variation and disease association studied using single nucleotide polymorphism tagging
Tissue Antigens, 2008, 71, 458-463
0.66Citations (PDF)
214Helminth Infection and Eosinophilia and the Risk of Plasmodium falciparum Malaria in 1- to 6-Year-Old Children in a Malaria Endemic Area
PLoS Neglected Tropical Diseases, 2008, 2, e164
3.036Citations (PDF)
215CD209 Genetic Polymorphism and Tuberculosis Disease
PLoS ONE, 2008, 3, e1388
2.3103Citations (PDF)
216Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial
PLoS ONE, 2008, 3, e1493
2.3103Citations (PDF)
217Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
PLoS ONE, 2008, 3, e1638
2.391Citations (PDF)
218Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans
PLoS ONE, 2008, 3, e2027
2.385Citations (PDF)
219Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
PLoS ONE, 2008, 3, e2921
2.346Citations (PDF)
220Blood-stage Challenge for Malaria Vaccine Efficacy Trials: A Pilot Study with Discussion of Safety and Potential Value
American Journal of Tropical Medicine and Hygiene, 2008, 78, 878-883
0.051Citations (PDF)
221The Induction and Persistence of T Cell IFN-γ Responses after Vaccination or Natural Exposure Is Suppressed by Plasmodium falciparum
Journal of Immunology, 2007, 179, 4193-4201
0.696Citations (PDF)
222Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria
Vaccine, 2007, 25, 8198-8202
3.16Citations (PDF)
223Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease
Molecular Immunology, 2007, 44, 3267-3270
2.241Citations (PDF)
224Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge
Infection and Immunity, 2007, 75, 5819-5826
2.744Citations (PDF)
225A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis
Nature Genetics, 2007, 39, 523-528
25.2417Citations (PDF)
226Extended Follow-Up Following a Phase 2b Randomized Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
PLoS ONE, 2007, 2, e707
2.358Citations (PDF)
227Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density
Malaria Journal, 2006, 5,
2.6110Citations (PDF)
228A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
Vaccine, 2006, 24, 2850-2859
3.188Citations (PDF)
229PTPN22 and invasive bacterial disease
Nature Genetics, 2006, 38, 499-500
25.255Citations (PDF)
230Aspects of Genetic Susceptibility to Human Infectious Diseases
Annual Review of Genetics, 2006, 40, 469-486
7.2249Citations (PDF)
231DimorphicPlasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming
European Journal of Immunology, 2006, 36, 1168-1178
3.223Citations (PDF)
232Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area
European Journal of Immunology, 2006, 36, 2264-2272
3.224Citations (PDF)
233Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence
Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9148-9153
7.5102Citations (PDF)
234A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya
PLOS Clinical Trials, 2006, 1, e29
2.9126Citations (PDF)
235Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein
Infection and Immunity, 2006, 74, 2706-2716
2.762Citations (PDF)
236A Polymorphism That Reduces RANTES Expression Is Associated with Protection from Death in HIV‐Seropositive Ugandans with Advanced Disease
Journal of Infectious Diseases, 2006, 194, 666-669
3.827Citations (PDF)
237Early Gamma Interferon and Interleukin-2 Responses to Vaccination Predict the Late Resting Memory in Malaria-Naïve and Malaria-Exposed Individuals
Infection and Immunity, 2006, 74, 6331-6338
2.722Citations (PDF)
238Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa
Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10364-10368
7.5108Citations (PDF)
239Variation in MICA and MICB genes and enhanced susceptibility to paucibacillary leprosy in South India
Human Molecular Genetics, 2006, 15, 2880-2887
2.945Citations (PDF)
240Prime-boost immunisation strategies for tuberculosis
Microbes and Infection, 2005, 7, 962-967
2.4106Citations (PDF)
241Direct processing and presentation of antigen from malaria sporozoites by professional antigen‐presenting cells in the induction of CD8 + T‐cell responses
Immunology and Cell Biology, 2005, 83, 307-312
2.663Citations (PDF)
242Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness
Hepatology, 2005, 41, 1383-1390
10.1128Citations (PDF)
243Calculation of Liver‐to‐Blood Inocula, Parasite Growth Rates, and Preerythrocytic Vaccine Efficacy, from Serial Quantitative Polymerase Chain Reaction Studies of Volunteers Challenged with Malaria Sporozoites
Journal of Infectious Diseases, 2005, 191, 619-626
3.8156Citations (PDF)
244Invariant Vα14 Chain NKT Cells Promote Plasmodium berghei Circumsporozoite Protein-Specific Gamma Interferon- and Tumor Necrosis Factor Alpha-Producing CD8+ T Cells in the Liver after Poxvirus Vaccination of Mice
Infection and Immunity, 2005, 73, 849-858
2.721Citations (PDF)
245Inverse Associations of Human Leukocyte Antigen and Malaria Parasite Types in Two West African Populations
Infection and Immunity, 2005, 73, 953-955
2.711Citations (PDF)
246Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara
Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4836-4841
7.5231Citations (PDF)
247Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720
Vaccine, 2005, 23, 857-864
3.173Citations (PDF)
248Pre-erythrocytic malaria vaccines: towards greater efficacy
Nature Reviews Immunology, 2005, 6, 21-32
53.8129Citations (PDF)
249QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION FOR MALARIA DIAGNOSIS AND ITS USE IN MALARIA VACCINE CLINICAL TRIALS
American Journal of Tropical Medicine and Hygiene, 2005, 73, 191-198
0.099Citations (PDF)
250A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses
Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 290-295
7.559Citations (PDF)
251Vitamin D Receptor Polymorphisms and Susceptibility to Tuberculosis in West Africa: A Case‐Control and Family Study
Journal of Infectious Diseases, 2004, 190, 1631-1641
3.8137Citations (PDF)
252Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin
Immunology, 2004, 112, 461-470
4.7112Citations (PDF)
253Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans
Nature Medicine, 2004, 10, 1240-1244
33.0547Citations (PDF)
254Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells
Cellular Immunology, 2004, 228, 15-19
2.519Citations (PDF)
255CD45 variant alleles: possibly increased frequency of a novel exon 4 CD45 polymorphism in HIV seropositive Ugandans
Immunogenetics, 2004, 56, 107-110
2.89Citations (PDF)
256Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction
Vaccine, 2004, 22, 4326-4331
3.118Citations (PDF)
257Malaria vaccine developments
Lancet, The, 2004, 363, 150-156
62.3165Citations (PDF)
258LARGE-SCALE CANDIDATE GENE STUDY OF LEPROSY SUSCEPTIBILITY IN THE KARONGA DISTRICT OF NORTHERN MALAWI
American Journal of Tropical Medicine and Hygiene, 2004, 71, 330-340
0.072Citations (PDF)
259LARGE-SCALE CANDIDATE GENE STUDY OF TUBERCULOSIS SUSCEPTIBILITY IN THE KARONGA DISTRICT OF NORTHERN MALAWI
American Journal of Tropical Medicine and Hygiene, 2004, 71, 341-349
0.0103Citations (PDF)
260Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection
Immunogenetics, 2003, 55, 362-369
2.8152Citations (PDF)
261Variants of the CD40 ligand gene are not associated with increased susceptibility to tuberculosis in West Africa
Immunogenetics, 2003, 55, 502-507
2.816Citations (PDF)
262Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection
Hepatology, 2003, 38, 1468-1476
10.1121Citations (PDF)
263Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
Nature Medicine, 2003, 9, 729-735
33.0541Citations (PDF)
264Genetic susceptibility to infectious disease
Trends in Microbiology, 2003, 11, 445-448
8.2134Citations (PDF)
265Heterologous Priming-Boosting Immunization of Cattle with Mycobacterium tuberculosis 85A Induces Antigen-Specific T-Cell Responses
Infection and Immunity, 2003, 71, 6906-6914
2.726Citations (PDF)
266Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case–control study
European Journal of Human Genetics, 2003, 12, 132-138
3.063Citations (PDF)
267EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION
American Journal of Tropical Medicine and Hygiene, 2003, 68, 421-430
0.035Citations (PDF)
268ASSOCIATION OF Fcγ RECEPTOR IIa (CD32) POLYMORPHISM WITH SEVERE MALARIA IN WEST AFRICA
American Journal of Tropical Medicine and Hygiene, 2003, 69, 565-568
0.085Citations (PDF)
269Induction of T Helper Type 1 and 2 Responses to 19-Kilodalton Merozoite Surface Protein 1 in Vaccinated Healthy Volunteers and Adults Naturally Exposed to Malaria
Infection and Immunity, 2002, 70, 1417-1421
2.737Citations (PDF)
270A Region of Chromosome 20 Is Linked to Leprosy Susceptibility in a South Indian Population
Journal of Infectious Diseases, 2002, 186, 1190-1193
3.865Citations (PDF)
271Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes
Vaccine, 2002, 20, 1039-1045
3.1158Citations (PDF)
272Chemokine-receptor genes and AIDS risk
Nature, 2002, 417, 140-140
37.922Citations (PDF)
273Transmission of hepatitis B virus infection in Gambian families revealed by phylogenetic analysis
Journal of Hepatology, 2001, 35, 99-104
4.298Citations (PDF)
274A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees
Vaccine, 2001, 19, 4595-4602
3.160Citations (PDF)
275THEGENOMICS ANDGENETICS OFHUMANINFECTIOUSDISEASESUSCEPTIBILITY
Annual Review of Genomics and Human Genetics, 2001, 2, 373-400
6.7237Citations (PDF)
276Immunogenetics and genomics
Lancet, The, 2001, 357, 2037-2041
62.364Citations (PDF)
277Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial
Lancet, The, 2001, 358, 1927-1934
62.3500Citations (PDF)
278Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis
Infection and Immunity, 2001, 69, 681-686
2.7220Citations (PDF)
279Induction of CD8 + T‐lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus
Immunology and Cell Biology, 2001, 79, 569-575
2.621Citations (PDF)
280Prevalence of HBV core promoter/precore/core mutations in Gambian chronic carriers
Journal of Medical Virology, 2001, 65, 664-670
3.724Citations (PDF)
281A major susceptibility locus for leprosy in India maps to chromosome 10p13
Nature Genetics, 2001, 27, 439-441
25.2173Citations (PDF)
282Genetics of susceptibitlity to human infectious disease
Nature Reviews Genetics, 2001, 2, 967-977
47.0457Citations (PDF)
283Strong HLA Class I–Restricted T Cell Responses in Dengue Hemorrhagic Fever: A Double‐Edged Sword?
Journal of Infectious Diseases, 2001, 184, 1369-1373
3.8171Citations (PDF)
284Genetic Regulation of Acquired Immune Responses to Antigens ofMycobacterium tuberculosis: a Study of Twins in West Africa
Infection and Immunity, 2001, 69, 3989-3994
2.795Citations (PDF)
285Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in west Africans.
American Journal of Tropical Medicine and Hygiene, 2001, 65, 733-735
0.066Citations (PDF)
286High frequencies of circulating IFN-γ-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restrictedMycobacterium tuberculosis epitope inM. tuberculosis-infected subjects without disease
European Journal of Immunology, 2000, 30, 2713-2721
3.294Citations (PDF)
287Improved method for distinguishing the human source of mosquito blood meals between close family members
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 572-574
1.425Citations (PDF)
288The immunology of malaria infection
Current Opinion in Immunology, 2000, 12, 437-441
5.2115Citations (PDF)
289In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope
Nature Medicine, 2000, 6, 337-342
33.0550Citations (PDF)
290Vaccines against intracellular infections requiring cellular immunity
Nature, 2000, 406, 793-798
37.9362Citations (PDF)
291Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3
Infection and Immunity, 2000, 68, 227-232
2.749Citations (PDF)
292Secretor Polymorphism and Human Immunodeficiency Virus Infection in Senegalese Women
Journal of Infectious Diseases, 2000, 181, 737-739
3.849Citations (PDF)
293Severe Malarial Anemia and Cerebral Malaria Are Associated with Different Tumor Necrosis Factor Promoter Alleles
Journal of Infectious Diseases, 1999, 179, 287-290
3.8235Citations (PDF)
294Induction of CD8+ T cells using heterologous prime-boost immunisation strategies
Immunological Reviews, 1999, 170, 29-38
6.5181Citations (PDF)
295Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming
Nature Medicine, 1999, 5, 565-571
33.098Citations (PDF)
296Broadly distributed T cell reactivity, with no immunodominant loci, to the pre-erythrocytic antigen thrombospondin-related adhesive protein ofPlasmodium falciparum in West Africans
European Journal of Immunology, 1999, 29, 1943-1954
3.247Citations (PDF)
297Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria Vaccine
Journal of Infectious Diseases, 1999, 180, 1656-1664
3.8154Citations (PDF)
298An Empirical Exploration of the (Δμ)2 Genetic Distance for 213 Human Microsatellite Markers
American Journal of Human Genetics, 1999, 65, 1125-1133
6.530Citations (PDF)
299Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime
Vaccine, 1999, 17, 589-596
3.197Citations (PDF)
300Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models
Vaccine, 1999, 18, 623-632
3.196Citations (PDF)
301Genetics and genomics of infectious disease susceptibility
British Medical Bulletin, 1999, 55, 401-413
4.076Citations (PDF)
302The Immunogenetics of Resistance to Malaria
Proceedings of the Association of American Physicians, 1999, 111, 272-277
3.056Citations (PDF)
303Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
Nature Medicine, 1998, 4, 397-402
33.0645Citations (PDF)
304Protection fromPlasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use
European Journal of Immunology, 1998, 28, 4345-4355
3.283Citations (PDF)
305Glucose-6-phosphate dehydrogenase deficiency and malaria
Journal of Molecular Medicine, 1998, 76, 581-588
3.7222Citations (PDF)
306Absence of an association between intercellular adhesion molecule 1, complement receptor 1 and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 312-316
1.485Citations (PDF)
307DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice
Vaccine, 1998, 16, 426-435
3.1126Citations (PDF)
308THE IMMUNOGENETICS OF HUMAN INFECTIOUS DISEASES
Annual Review of Immunology, 1998, 16, 593-617
29.5527Citations (PDF)
309Heterogeneity of Microsatellite Mutations Within and Between Loci, and Implications for Human Demographic Histories
Genetics, 1998, 148, 1269-1284
4.2155Citations (PDF)
310Rapid Effector Function in CD8+ Memory T Cells
Journal of Experimental Medicine, 1997, 186, 859-865
9.2633Citations (PDF)
311Genetic analysis of host–parasite coevolution in human malaria
Philosophical Transactions of the Royal Society B: Biological Sciences, 1997, 352, 1317-1325
3.772Citations (PDF)
312A protein particle vaccine containing multiple malaria epitopes
Nature Biotechnology, 1997, 15, 1280-1284
29.8154Citations (PDF)
313Heterozygote advantage for HLA class-II type in hepatitis B virus infection
Nature Genetics, 1997, 17, 11-12
25.2297Citations (PDF)
314Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors
Journal of Immunological Methods, 1997, 210, 65-77
1.479Citations (PDF)
315A distinctive peptide binding motif for HLA-DRB1 * 0407, an HLA-DR4 subtype not associated with rheumatoid arthritis
Immunogenetics, 1997, 45, 229-232
2.816Citations (PDF)
316T-cell receptor variable alpha ( TCRAV) polymorphisms in European, Chinese, South American, AfroCaribbean, and Gambian populations
Immunogenetics, 1997, 47, 124-130
2.85Citations (PDF)
317Genetic susceptibility to multifactorial diseases
Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 369-371
1.41Citations (PDF)
318Genetic linkage of mild malaria to the major histocompatibility complex in Gambian children: study of affected sibling pairs: Table 1
BMJ: British Medical Journal, 1997, 315, 96-97
0.167Citations (PDF)
319Reverse immunogenetics: from HLA-disease associations to vaccine candidates
Trends in Molecular Medicine, 1996, 2, 38-45
2.563Citations (PDF)
320Genetics of infectious disease resistance
Current Opinion in Genetics and Development, 1996, 6, 348-353
3.265Citations (PDF)
321Cytotoxic T lymphocytes toPlasmodium falciparum epitopes in an area of intense and perennial transmission in Tanzania
European Journal of Immunology, 1996, 26, 773-779
3.254Citations (PDF)
322Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization
European Journal of Immunology, 1996, 26, 1951-1959
3.289Citations (PDF)
323Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood
European Journal of Immunology, 1995, 25, 1783-1787
3.244Citations (PDF)
324Association of hepatitis B surface antigen carriage with severe malaria in Gambian children
Nature Medicine, 1995, 1, 374-375
33.063Citations (PDF)
325Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria
Nature, 1994, 371, 508-511
37.91,186Citations (PDF)
326HLA, malaria and dominant protective associations
Parasitology Today, 1992, 8, 57
0.05Citations (PDF)
327Molecular analysis of the association of HLA-B53 and resistance to severe malaria
Nature, 1992, 360, 434-439
37.9648Citations (PDF)
328Common West African HLA antigens are associated with protection from severe malaria
Nature, 1991, 352, 595-600
37.91,527Citations (PDF)
329Mapping immune variation and var gene switching in naive hosts infected with Plasmodium falciparum
ELife, 0, 10,
1.631Citations (PDF)
330BIRC6 modifies risk of invasive bacterial infection in Kenyan children
ELife, 0, 11,
1.68Citations (PDF)